Investigation of the structure-activity relationship in a series of new LVV- and VV-hemorphin-7 analogues designed as potential anticonvulsant agents

Abstract

In the present study, a series of new analogues of both LVV- and VV-hemorphin-7 have been synthesized and characterized. They were modified at the N- and C-terminus with varied amino acids (Ile, D-Leu, D-Val, D-Phe) and enantiopure chiral S- and R- α-aminophosphonic acids ((dimethoxyphosphoryl)methyl)-valine and ((dimethoxyphosphoryl) methyl)-leucine) to optimize the physicochemical properties and to enhance their anticonvulsant potency. The novel peptide analogues were prepared by solid-phase peptide synthesis-Fmoc-strategy. Their structure-property relationship was studied by FT-IR spectroscopy and electrochemical methods. The lipophilicity is also presented. The anticonvulsant activity of peptide analogues, administered intracerebroventricularly, at doses of 1, 2.5, and 5 μg/10 μL, respectively, was explored by 6-Hz psychomotor seizure test, maximal electroshock test (MES) and a timed intravenous pentylenetetrazole (ivPTZ) infusion test in mice. The potential neurological toxicity of the substances was checked by a rotarod test. The H7 was used as a positive control. The H7-1 peptide analogue was the most active molecule against the psychomotor seizures, while H7-6 and H7-7 showed comparable to the positive group H7 potency in the MES test. The H7-5 to H7-8 analogues at the two tested doses of 2.5 and 5 μg/10 μl raised the threshold against ivPTZ-induced myoclonic, clonic, and tonic seizures. None of the hemorphin analogues exhibited neurotoxicity in the rotarod test. In conclusion, our results suggest that modified at N- and C-terminus of certain amino acids in the hemorphin analogues have a crucial role as a basis to design new LVV- and VV-hemorphin-7 analogues for experimental and clinical use.

Keywords: Electrochemistry; FT-IR spectroscopy; Hemorphins; Partition coefficient; Rotarod test; Seizure tests.